System Certification ISO 9001:2000
Exbio Antibodies CZ / SK eShop
by categories | a-z list | Application type: Flow Cytometry | Immunohistochemistry | Functional Studies

Mouse Monoclonal to HLA-E

3D12 (IgG1)

Technical Information Request    Inquiry for Bulk Prices

Product No. Form Quantity Stock Price Datasheet Shop
New 11-824-C100 purified 0.1 mg yes choose region PDF datasheetHTML datasheet buy
New 1P-824-C100 PE 0.1 mg yes choose region PDF datasheetHTML datasheet buy
- In stock! Ready for immediate despatch - Manufacture on order


HLA-E (Human Leukocyte Antigen E) is a non-classical MHC I antigen, which is important for dialogue with NK cells and their regulation through interaction with CD94/NKG2 receptor. Like other MHC I molecules, transmembrane HLA-E molecule (45 kDa) associates with beta2 microglobulin. Unlike HLA-G, expression of HLA-E molecules is not so restricted, but it has been detected at least at mRNA level in virtually all cells and tissues examined. In peripheral blood, HLA-E protein is expressed at least in all mononuclear cells, but in different quantity (B cells and monocytes more than T cells and NK cells).


The mouse monoclonal antibody 3D12 (also known as 3D12HLA-E) recognizes native extracellular part of HLA-E, an ubiquitously expressed non-classical MHC class I molecule, as well as free HLA-E.

Regulatory Status

Species Reactivity:

  • Human

Negative Species:


  • Flow Cytometry
  • Immunoprecipitation
Usage note:
Indicated dilutions are recommended starting points for use of this product. Working concentrations should be determined by the investigator.

Product Specific References

  • *Lee N, Llano M, Carretero M, Ishitani A, Navarro F, Lˇpez-Botet M, Geraghty DE: HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5199-204. [Abstract]
  • *McMurtrey C, Harriff MJ, Swarbrick GM, Duncan A, Cansler M, Null M, Bardet W, Jackson KW, Lewinsohn DA, Hildebrand W, Lewinsohn DM: T cell recognition of Mycobacterium tuberculosis peptides presented by HLA-E derived from infected human cells. PLoS One. 2017 Nov 27;12(11):e0188288. [Abstract]
  • Allard M, Tonnerre P, Nedellec S, Oger R, Morice A, Guilloux Y, Houssaint E, Charreau B, Gervois N: HLA-E-restricted cross-recognition of allogeneic endothelial cells by CMV-associated CD8 T cells: a potential risk factor following transplantation. PLoS One. 2012;7(11):e50951. [Abstract]
  • *Sensi M, Pietra G, Molla A, Nicolini G, Vegetti C, Bersani I, Millo E, Weiss E, Moretta L, Mingari MC, Anichini A: Peptides with dual binding specificity for HLA-A2 and HLA-E are encoded by alternatively spliced isoforms of the antioxidant enzyme peroxiredoxin 5. Int Immunol. 2009 Mar;21(3):257-68. [Abstract]
  • *Ravindranath MH, Pham T, El-Awar N, Kaneku H, Terasaki PI: Anti-HLA-E mAb 3D12 mimics MEM-E/02 in binding to HLA-B and HLA-C alleles: Web-tools validate the immunogenic epitopes of HLA-E recognized by the antibodies. Mol Immunol. 2011 Jan;48(4):423-30. [Abstract]
  • *Tremante E, Lo Monaco E, Ingegnere T, Sampaoli C, Fraioli R, Giacomini P: Monoclonal antibodies to HLA-E bind epitopes carried by unfolded β2 m-free heavy chains. Eur J Immunol. 2015 Aug;45(8):2356-64. [Abstract]
  • *Lo Monaco E, Tremante E, Cerboni C, Melucci E, Sibilio L, Zingoni A, Nicotra MR, Natali PG, Giacomini P: Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. Neoplasia. 2011 Sep;13(9):822-30. [Abstract]
  • For research use only. Not for drug, diagnostic or other use.

    Example Data

    Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO┤s term and conditions which are available at
    © 2003 EXBIO. All rights reserved.
    terms and conditions | privacy policy